Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Gerhard Koenig
AddedFeb 15, 2024
UpdatedMay 31, 2026
Gerhard Koenig

Gerhard Koenig

Board Member, Quartet Medicine

CrunchbaseThe Org

Gerhard Koenig's Career

Quartet Medicine
Quartet Medicine

Cambridge, MA, US

Board Member· Board
Arkuda Therapeutics
Arkuda Therapeutics

Watertown, MA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Gerhard Koenig's Career

Quartet Medicine
Quartet Medicine
Series A$23M72013Cambridge, MA, US
Board Member· Board

Leadership at Quartet Medicine

Mark H N CorriganMark H N CorriganBoard Member
Henry B. SkinnerHenry B. SkinnerBoard Member
John CreecyJohn CreecyBoard Member
Kevin PojasekKevin PojasekFounder
Arkuda Therapeutics
Arkuda Therapeutics
Series B$108M302018Watertown, MA, US
Founder

Leadership at Arkuda Therapeutics

Bruce BoothBruce BoothBoard Member
Johannes FruehaufJohannes FruehaufBoard Member

Similar to Arkuda Therapeutics

Lysosomal TherapeuticsLysosomal TherapeuticsCambridge, MA, USDrug Developmentest. 2011Lysosomal TherapeuticsCambridge, MA, US · est. 2011

US-based Lysosomal Therapeutics Inc innovates in neurodegeneration research, developing treatments for severe neurological diseases.

Series A · $24.8M5
Denali TherapeuticsDenali TherapeuticsSan Francisco, CA, USBiotechest. 2015Denali TherapeuticsSan Francisco, CA, US · est. 2015

Denali Therapeutics, a US-based biotech firm, develops medicines for neurodegenerative diseases.

Public · $622M427
Endlyz TherapeuticsEndlyz TherapeuticsBoston, MA, USTherapeuticsest. 2021Endlyz TherapeuticsBoston, MA, US · est. 2021

Boston-based medical organization developing therapeutics for neurodegenerative diseases.

Angel · $3.3M50
Aprinoia TherapeuticsAprinoia TherapeuticsCambridge, MA, USDiagnostic Tools, Therapiesest. 2015Aprinoia TherapeuticsCambridge, MA, US · est. 2015

APRINOIA: A global biotech leader in precision neuroscience, innovating diagnostic tools and therapies for neurodegenerative diseases.

Series A · $61.9M75

Gerhard Koenig's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Gerhard Koenig

Afshin SafaviAfshin SafaviBoard Member · Chimeron Bioastrid Barreraastrid BarreraCo-Founder · Revolution PrepJohn DonahoeJohn DonahoeBoard Member · ServiceNow VenturesEmeryEmeryCo-Founder · KadoLucas HendricksLucas HendricksCo-Founder · KairosDaniel StarlingDaniel StarlingCo-Founder · BarBird